Trial Profile
The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms SPRINT
- 12 Nov 2023 Results published in the Journal of Clinical Oncology
- 11 Jul 2022 Planned End Date changed from 1 Sep 2022 to 18 Nov 2026.
- 11 Jul 2022 Planned primary completion date changed from 8 Jun 2022 to 18 Nov 2022.